



台灣肺癌研究學會

Taiwan Association for the Study of Lung Cancer

2024 TASLC International Symposium on Treatment
Advances in Lung Cancer

Jan.13^{Sat} ~14^{Sun} 2024

臺大醫院癌醫中心分院
國際會議中心
National Taiwan University Cancer Center
International Conference Center



線上報名連結

1/13 (Sat.) 12:00-18:00

Time	Topic	Speaker	Moderator
Satellite Symposium			
12:00-12:40	Daiichi-Sankyo & AstraZeneca Evolving Treatment Landscape of NSCLC with HER2 Alterations	Daniel Tan	James CH Yang
12:40-13:20	Amgen & Merck Unlocking the potential for the treatment of SCLC and MET alterations	Yasushi Goto	Chao-Chi Ho
Plenary Lecture			
13:30-13:40	Opening Address	James CH Yang	
13:40-14:05	Carcinogenesis and early detection of lung cancer in never smokers	Pan-Chyr Yang	James CH Yang
14:05-14:20	Local ablation of lung tumors	Yeun-Chung Chang	Gee-Cheng Chang
14:20-14:35	Neoadjuvant IO+Chemotherapy for early stage NSCLC - Surgeon's perspectives	Jay M. Lee	Jin-Shing Chen
14:35-14:50	Neoadjuvant IO+Chemotherapy for early stage NSCLC - Medical Oncologist's perspectives	Heather Wakelee	Jin-Yuan Shih
14:50-15:00	Case presentation: surgery after neoadjuvant IO + chemotherapy	Natalie Lui	Chih-Yi Chen
15:00-15:30	Panel Discussion	Heather Wakelee	
15:30-16:00	Break		
16:00-16:15	Update of treatment for inoperable locally advanced NSCLC	Rina Hui	Kang-Yun Lee
16:15-16:30	Adjuvant treatment for resectable stage I-III NSCLC	Jih-Hsiang Lee	Feng-Ming Hsu
16:30-16:45	Perioperative therapy for driver mutation-positive early stage lung cancer	Chee Khoo Lee	Tsung-Ying Yang
16:45-17:00	Genomic analysis requirement for all stages of NSCLC	Fernando Lopez-Rios	Teh-Ying Chou
17:00-17:20	Panel Discussion	Alex Adjei	
Satellite Symposium			
17:20-18:00	Johnson & Johnson Clinical experience and perspectives sharing from South Korea on the use of Amivantamab in rare and common EGFRm NSCLC	Myung-Ju Ahn	Chong-Jen Yu

1/14 (Sun.) 08:20-15:15

Time	Topic		Speaker	Moderator
Satellite Symposium				
08:20-09:00	Boehringer Ingelheim	Experimental Therapeutics & New Drug Development in DLL3, Her2 and P53	Tetsuya Mitsudomi	Wen-Cheng chang
Plenary Lecture				
09:00-09:30	Novel immunotherapy strategies		Solange Peters	Inn-Wen Chong
09:30-09:45	Novel EGFR TKIs		Daniel Tan	Chien-Chung Lin
09:45-10:00	Target Exon20 insertion mutation of EGFR and HER2		Byoung Chul Cho	Jin-Yuan Shih
10:00-10:15	How to choose first line treatment for metastatic EGFRm NSCLC		Chao-Hua Chiu	Chao-Chi Ho
10:15-10:25	Case presentation		Pei Jye Voon	Jen-Chang Ko
10:25-10:45	Panel Discussion		Fred R. Hirsch	
10:45-11:10	Coffee Break			
11:10-11:25	Novel antibody drug conjugates for lung cancer: monotherapy		Egbert Smit	Ching-Liang Ho
11:25-11:40	Novel antibody drug conjugates for lung cancer: combination studies		Yasushi Goto	Chia-Chi (Josh) Lin
11:40-11:55	Novel MET, RET, NTRK inhibitors and novel targets		Herbert Loong	Chung-Kan Peng
11:55-12:10	Case presentation		Wei-Yu Liao	Chao-Hua Chiu
12:10-12:30	Panel Discussion		Egbert Smit	
Luncheon Symposium				
12:30-13:10	MSD	Pembrolizumab in First-Line Treatment of NSCLC: Survival Outcomes and Impact on Standard of Care	Chee Khoon Lee	Inn-Wen Chong
13:10-13:30	Lunch break			
Plenary Lecture				
13:30-13:45	Novel checkpoint inhibitors		Chia-Chi (Josh) Lin	James CH Yang
13:45-14:00	Novel bispecific antibodies: amivantamab, PD1/CTLA4, PD1/TIGIT		Myung-Ju Ahn	Chong-Jen Yu
14:00-14:15	IO for EGFRm NSCLC, is there any role?		Tetsuya Mitsudomi	Pan-Chyr Yang
14:15-14:25	Case presentation		Ching-Yao Yang	Han-Sui Hsu
14:25-14:50	Panel Discussion		James CH Yang	
14:50-15:05	Forecast for future lung cancer treatment		Karen Kelly	James CH Yang
15:05-15:15	Conclusion remarks and farewell		Chong-Jen Yu	